| Immune‐related adverse events as a biomarker in non‐melanoma patients treated with programmed cell death 1 inhibitors J Judd, M Zibelman, E Handorf, J O'Neill, C Ramamurthy, S Bentota, ... The oncologist 22 (10), 1232-1237, 2017 | 128 | 2017 |
| Retzius-sparing robot-assisted radical prostatectomy leads to durable improvement in urinary function and quality of life versus standard robot-assisted radical prostatectomy … J Egan, S Marhamati, FLF Carvalho, M Davis, J O’Neill, H Lee, JH Lynch, ... European urology 79 (6), 839-857, 2021 | 71 | 2021 |
| Defects in DNA repair genes confer improved long-term survival after cisplatin-based neoadjuvant chemotherapy for muscle-invasive bladder cancer B Miron, JH Hoffman-Censits, F Anari, J O’Neill, DM Geynisman, ... European urology oncology 3 (4), 544-547, 2020 | 62 | 2020 |
| Neoadjuvant dose-dense gemcitabine and cisplatin in muscle-invasive bladder cancer: results of a phase 2 trial F Anari, J O’Neill, W Choi, DYT Chen, M Haseebuddin, A Kutikov, ... European urology oncology 1 (1), 54-60, 2018 | 36 | 2018 |
| Cystoscopy and systematic bladder tissue sampling in predicting pT0 bladder cancer: a prospective trial M Zibelman, AM Asghar, DC Parker, J O’Neill, S Wei, RE Greenberg, ... The Journal of Urology 205 (6), 1605-1611, 2021 | 16 | 2021 |
| The onset of embryo maturation in Arabidopsis is determined by its developmental stage and does not depend on endosperm cellularization JP O'Neill, KT Colon, PD Jenik The Plant Journal 99 (2), 286-301, 2019 | 14 | 2019 |
| Defects in DNA repair genes and long-term survival in cisplatin-based neoadjuvant chemotherapy for muscle invasive bladder cancer (MIBC). B Miron, EA Ross, F Anari, J O'Neill, JH Hoffman-Censits, MR Zibelman, ... Journal of Clinical Oncology 37 (15_suppl), 4536-4536, 2019 | 4 | 2019 |
| A phase 1 study of nivolumab in combination with interferon-gamma for patients with advanced solid tumors M Zibelman, AW MacFarlane IV, K Costello, T McGowan, J O’Neill, ... Nature Communications 14 (1), 4513, 2023 | 3 | 2023 |
| Effect of exogenous interferon-gamma (IFN-gamma) on peripheral blood immune markers as part of a phase I clinical trial of combined IFN-gamma with nivolumab (Nivo) in patients … MR Zibelman, A Macfarlane, RK Alpaugh, E Dulaimi, K Costello, J O'Neill, ... Journal of Clinical Oncology 35 (7_suppl), 97-97, 2017 | 2 | 2017 |
| LBA5 INITIAL RESULTS OF A PROSPECTIVE COHORT STUDY EVALUATING RELIABILITY OF ENDOSCOPIC EVALUATION IN PREDICTING PT0 DISEASE AT THE TIME OF RADICAL CYSTECTOMY: WHERE AND HOW … D Parker, A Asghar, J O'Neill, R Greenberg, M Smaldone, D Chen, ... The Journal of Urology 199 (4S), e578-e579, 2018 | 1 | 2018 |
| Immune related adverse events as a biomarker in non-melanoma patients treated with programmed death 1 inhibitors (PD-1Is). J Judd, MR Zibelman, E Handorf, J O'Neill, S Bentota, J Doyle, RG Uzzo, ... Journal of Clinical Oncology 34 (15_suppl), 3069-3069, 2016 | 1 | 2016 |
| Association of eosinophila with efficacy in non-melanoma patients treated with programmed death 1 inhibitors. MR Zibelman, J Judd, E Handorf, J O'Neill, S Bentota, J Doyle, RG Uzzo, ... Journal of Clinical Oncology 34 (15_suppl), e14510-e14510, 2016 | 1 | 2016 |
| Systematic Endoscopic Evaluation in Predicting pT0 Bladder Cancer: A Prospective Trial M Zibelman, AM Asghar, DC Parker, J O’Neill, S Wei, RE Greenberg, ... The Journal of urology 205 (6), 1605, 2021 | | 2021 |
| PD50-07 SYSTEMATIC ENDOSCOPIC EVALUATION FALLS SHORT IN PREDICTING PT0 BLADDER CANCER: A PROSPECTIVE TRIAL A Asghar, D Parker, J O'Neill, R Greenberg, M Smaldone, D Chen, ... Journal of Urology 203, e1010, 2020 | | 2020 |
